The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones.

By K. Setchell, N. Brown, E. Lydeking-Olsen. Journal of NutriLife, 2002

1,237 citations recorded by the source corpus.

Subfields: Genetics, Nutrition and Dietetics, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/90bf1cdc9d01c0bb9cf49a5f21c6187edcd1c288

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Pathology and Forensic Medicine

Citations in the corpus

The pros and cons of phytoestrogens (2010, neutral): “How these metabolic phenotypes affect human health outcomes is poorly characterized but considerable attention has recently been devoted to understanding the significance of this metabolic step because equol has a higher estrogenic potency than daidzein [251] and some researchers have hypothesized t”
Anthocyanins: natural colorants with health-promoting properties. (2010, background): “Equol as a colonic metabolite of daidzein is more estrogenic than daidzein and the other metabolites of isoflavones (Setchell et al. 2002).”
Organization of GC/MS and LC/MS metabolomics data into chemical libraries (2010, background): “The ions that were grouped (Figure 6, panel A) as originating from an unknown source were later identified as Equol (4’,7-isoflavandiol), an isoflavandiol metabolized from daidzein, a type of isoflavone, by bacterial flora in the intestines [9] (Figure 6, panel B).”
Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic Diseases (2013, neutral): “synthesizing equol, as it S-enantiomer, and those who lack the microbes to do so (225, 409).”
Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. (2005, background): “There is emerging evidence that “equol producers” demonstrate better effects on some biomarkers, such as bone mineral density, after isoflavone consumption, compared with nonproducers (109).”
Polyphenols: antioxidants and beyond. (2005, background): “The importance of microbial metabolites has been emphasized in some recent studies, as exemplified by equol, the major metabolite of daidzein (20).”
Polyphenols, dietary sources and bioavailability. (2007, background): “equol appears to have phytoestrogenic properties even greater than those of the original isoflavone [79]; enterolactone and enterodiol, produced from linseed, have agonistic or antagonistic effects on estrogens [80, 81].”
The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility (2016, background): “Isoflavones can be biotransformed by β-glucosidase from gut microbiota into their aglycones for increased bioavailability [70,71].”
Bioactivity of dietary polyphenols: The role of metabolites (2020, background): “Genistein showed a significantly higher level of RBA for ERb (18.13) than for ERa (3.1).”
Polyphenols: food sources and bioavailability. (2004, background): “Similarly, equol produced from soya daidzein appears to have phytoestrogenic properties equivalent to or even greater than those of the original isoflavone (151, 152).”
Flavonoid Bioavailability and Attempts for Bioavailability Enhancement (2013, background): “Equol can be responsible for the clinical effectiveness of isoflavones as its bioactivity was reported to be stronger than daidzein [65].”
Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. (2005, background): “” Equol producers may gain more benefits from soy consumption than do nonproducers (119, 120).”